UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 66

Sortiert nach

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

The New England journal of medicine, 2017-11, Vol.377 (19), p.1813-1823

2017

Link zum Volltext

Verfügbarkeit prüfen

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

Journal of clinical oncology, 2020-11, Vol.38 (31), p.3592-3603

2020

Link zum Volltext

Verfügbarkeit prüfen

Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

Journal of thoracic oncology, 2021-12, Vol.16 (12), p.2091-2108

2021

Link zum Volltext

Verfügbarkeit prüfen

Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study

International journal of clinical oncology, 2022-12, Vol.27 (12), p.1828-1838

2022

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of the drug–drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach

CPT: pharmacometrics and systems pharmacology, 2024-04, Vol.13 (4), p.624-637

2024

Link zum Volltext

Verfügbarkeit prüfen

Population pharmacokinetic and exposure‐response analyses from ALTA‐1L: Model‐based analyses supporting the brigatinib dose in ALK‐positive NSCLC

Clinical and translational science, 2022-05, Vol.15 (5), p.1143-1154

2022

Link zum Volltext

Verfügbarkeit prüfen

Comparative Efficacy of Treatments for Previously Treated Advanced or Metastatic Non-Small-Cell Lung Cancer: A Network Meta-Analysis

Advances in therapy, 2018-07, Vol.35 (7), p.1035-1048

2018

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials

JTO clinical and research reports, 2022-09, Vol.3 (9), p.100385-100385, Article 100385

2022

Link zum Volltext

Verfügbarkeit prüfen

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

The lancet oncology, 2016-07, Vol.17 (7), p.984-993

2016

Link zum Volltext

Verfügbarkeit prüfen

Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.452-463

2021

Link zum Volltext

Verfügbarkeit prüfen

Molecular analysis of circulating tumor DNA (ctDNA) in patients (pts) with EGFR exon 20 insertion-positive (ex20ins+) advanced NSCLC treated with mobocertinib

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9108-9108

2022

Link zum Volltext

Verfügbarkeit prüfen

Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor

Clinical pharmacokinetics, 2023-08, Vol.62 (8), p.1063-1079

2023

Link zum Volltext

Verfügbarkeit prüfen

Brigatinib in Japanese patients with ALK‐positive non‐small‐cell lung cancer: Final results of the phase 2 J‐ALTA trial

Cancer science, 2023-09, Vol.114 (9), p.3698-3707

2023

Link zum Volltext

Verfügbarkeit prüfen

Brigatinib in Japanese patients (pts) with ALK + NSCLC: Final results from the phase 2 J-ALTA trial

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9075-9075

2022

Link zum Volltext

Verfügbarkeit prüfen

Brigatinib in Japanese patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC): First results from the J-ALTA tyrosine kinase inhibitor (TKI)-naive expansion cohort

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9042-9042

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2781: De novo molecular mechanisms of resistance to mobocertinib

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.2781-2781

2022

Link zum Volltext

Verfügbarkeit prüfen

Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States

The oncologist (Dayton, Ohio), 2022-09, Vol.27 (9), p.790-798

2022

Link zum Volltext

Verfügbarkeit prüfen

Matching-adjusted indirect comparison (MAIC) of mobocertinib versus amivantamab in patients with non–small cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9115-9115

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2)

Journal of thoracic oncology, 2022-12, Vol.17 (12), p.1404-1414

2022

Link zum Volltext

Verfügbarkeit prüfen

81 - Mobocertinib in previously treated patients with EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): updated results from a phase 1/2 study

Lung cancer (Amsterdam, Netherlands), 2023-04, Vol.178, p.S35-S35

2023

Link zum Volltext

Verfügbarkeit prüfen

Mobocertinib in previously treated patients with EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): updated results from a phase 1/2 study

Lung cancer (Amsterdam, Netherlands), 2023-04, Vol.178, p.S35

2023

Link zum Volltext

Verfügbarkeit prüfen

Health-related quality of life (HRQoL) results from ALTA-1L: Phase 3 study of brigatinib vs crizotinib as first-line (1L) ALK therapy in advanced ALK+ non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.9084-9084

2019

Link zum Volltext

Verfügbarkeit prüfen

Phase 2 study of brigatinib in patients (pts) with anaplastic lymphoma kinase (ALK)−positive, advanced non–small cell lung cancer (NSCLC) that progressed on alectinib or ceritinib

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.TPS9115-TPS9115

2019

Link zum Volltext

Verfügbarkeit prüfen

Brigatinib in Japanese ALK positive NSCLC patients previously treated with ALK tyrosine kinase inhibitors: J-ALTA

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.9537-9537

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 66

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(60)
Mit Volltextzugriff
(62)

Publikationsform

Artikel
(65)
Tagungsberichte
(1)

Sprache

Englisch
(62)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Science & Technology
(30)
Life Sciences & Biomedicine
(24)
Humans
(22)
Oncology
(19)
Lung Neoplasms - Drug Therapy
(16)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(14)
Anaplastic Lymphoma Kinase
(12)
Mutation
(10)
Brigatinib
(9)
Lung Cancer
(9)
Lung Neoplasms - Genetics
(9)
Middle Aged
(9)
Aged
(8)
Carcinoma, Non-Small-Cell Lung - Genetics
(8)
Protein Kinase Inhibitors - Therapeutic Use
(8)
Adult
(7)
Crizotinib
(7)
Female
(7)
Male
(7)
Metastasis
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

Dabrafenib plus trametinib in patients with previously treated BRAFV600E -mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study

Evaluation of the drug–drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach

Population pharmacokinetic and exposure‐response analyses from ALTA‐1L: Model‐based analyses supporting the brigatinib dose in ALK‐positive NSCLC

Comparative Efficacy of Treatments for Previously Treated Advanced or Metastatic Non-Small-Cell Lung Cancer: A Network Meta-Analysis

Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial

Molecular analysis of circulating tumor DNA (ctDNA) in patients (pts) with EGFR exon 20 insertion-positive (ex20ins+) advanced NSCLC treated with mobocertinib

Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor

Brigatinib in Japanese patients with ALK‐positive non‐small‐cell lung cancer: Final results of the phase 2 J‐ALTA trial

Brigatinib in Japanese patients (pts) with ALK + NSCLC: Final results from the phase 2 J-ALTA trial

Brigatinib in Japanese patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC): First results from the J-ALTA tyrosine kinase inhibitor (TKI)-naive expansion cohort

Abstract 2781: De novo molecular mechanisms of resistance to mobocertinib

Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States

Matching-adjusted indirect comparison (MAIC) of mobocertinib versus amivantamab in patients with non–small cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins)

Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2)

81 - Mobocertinib in previously treated patients with EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): updated results from a phase 1/2 study

Mobocertinib in previously treated patients with EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): updated results from a phase 1/2 study

Health-related quality of life (HRQoL) results from ALTA-1L: Phase 3 study of brigatinib vs crizotinib as first-line (1L) ALK therapy in advanced ALK+ non-small cell lung cancer (NSCLC)

Phase 2 study of brigatinib in patients (pts) with anaplastic lymphoma kinase (ALK)−positive, advanced non–small cell lung cancer (NSCLC) that progressed on alectinib or ceritinib

Brigatinib in Japanese ALK positive NSCLC patients previously treated with ALK tyrosine kinase inhibitors: J-ALTA

Suchergebnisse filtern